Nexium Direct Purchasers Win Class Cert. In Antitrust MDL

Law360, New York (December 11, 2013, 5:25 PM ET) -- A Massachusetts judge granted class certification on Wednesday to a group of direct purchasers alleging AstraZeneca PLC and others breached antitrust laws by engineering the delay of a generic form of heartburn drug Nexium.

U.S. District Judge William G. Young noted that the defendants raised many of the same objections in their efforts to avoid certification of a class of end-buyers he approved in mid-November, and said the same analysis applies “with full force and effect” to the direct purchasers’ certification bid.

The direct purchasers claim...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required

Case Information

Case Title

In Re: Nexium (Esomeprazole) Antitrust Litigation

Case Number

1:12-md-02409

Court

Massachusetts

Nature of Suit

Anti-Trust

Judge

William G. Young

Law360 Coverage

Date Filed

December 7, 2012

Sections

Law Firms Mentioned

Companies Mentioned

Related Articles